Disclosed is a dichloronathtelene and quinoline compounds having a structure of Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt or solvate thereof: wherein n is an integer selected from 0 to 2; D is CX-Ar1 or N-Ar1; m is 1; each X is independently H or OH; Ar1 is defined in the specification V and W are independently selected from H or OR9 ; wherein R9 is selected from H, alkyl, heteroalkyl, aryl, heteroaryl, and heterocycloalkyl; each R1 and R2 is independently H, halogen, CN, substituted or unsubstituted alkyl, or heteroalkyl; and R3 and R4 are independently H, alkyl, or heteroalkyl and any enantiomer, diastereoisomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof. Also disclosed is the use of said compound for treating a central nervous system disorder, wherein said central nervous system disorder is selected from depression, fibromyalgia, pain, sleep apnea, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), restless leg syndrome, schizophrenia, anxiety, obsessive compulsive disorder, post-traumatic stress disorder, seasonal affective disorder (SAD), premenstrual dysphoria, and a neurodegenerative disease.
Tetralone-based monoamine reuptake inhibitors